The principle of molecular targeting of NETs with PRRT has also been applied to other cancer entities, for example in the treatment of prostate cancer with the prostate-specific membrane antigen radioligand PSMA-RLD [17,18,19,20]. This evidence concerns the gene FOLH1 and prostate carcinoma.